2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2365 Cumulative anaerobic antibiotic burden correlates with survival and toxicity following anti-CD19 CAR T cell therapy

Jiayi Xie, PhD, Amy Zhang, MPH2, Prisca Lim3, Sarah Elkordy4, Alicia Darwin5, Ishan Paranjpe, MD6, Nancy Torres Luna7, Rong Lu8, Taylor Soleil Jones9, Nadia Kaveh10, Manish K. Saha11, Adam Groth12, Jonathan Huggins13, Tessa Andermann, MD, MPH14, Melody Smith, MD,MS15
1 Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, United States
2 Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, United States
3 Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
4 Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, United States
5 Department of Hematology and Medical Oncology, California Pacific Medical Center, Sutter Health, San Francisco, California, United States, Department of Medicine, Stanford University Hospital, Stanford University, Stanford, California, United States
6 Department of Medicine, Stanford University Hospital, Stanford University, Stanford, California, United States
7 Department of Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida, United States, Department of Medicine, Stanford University Hospital, Stanford University, Stanford, California, United States
8 Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, United States
9 Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, United States
10 Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, United States
11 Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
12 Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
13 Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States
14 Institute for Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
15 Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, California, United States

Background: We and others have demonstrated that anaerobically-targeted antibiotic administration in the weeks before chimeric antigen receptor T cell (CAR-T) infusion is associated with worse overall survival (OS). However, a critical knowledge gap exists on the impact of post-infusion antibiotics. We investigated the impact of peri- (pre- and post-) infusion antibiotic exposure, quantifying the association between anaerobic antibiotic activity and duration on clinical outcomes and the gut microbiome in anti-CD19 CAR-T recipients. 

Methods: In a large multi-center clinical retrospective cohort of adult patients undergoing anti-CD19 CAR-T therapy at Stanford University, Duke University, and the University of North Carolina–Chapel Hill (UNC), we used Cox proportional hazards and logistic regression to evaluate the association between anaerobically-active antibiotics and clinical outcomes. We classified anaerobic activity through a binary clinical categorization of anaerobically-active or not, and through the novel Anaerobic Antibiotic Index (AAI), based on in vitro antibiotic activity to quantify the cumulative antibiotic pressure against clinically relevant anaerobic bacteria (Mackow et al. CID [in-press], 2026). Additionally, we prospectively analyzed longitudinally collected stool samples (pre-CAR through 4 weeks post-CAR) from CD19 CAR-T recipients (Stanford, UNC) investigating associations between antibiotic activity and changes in the gut microbiome. We performed shotgun metagenomic sequencing and taxonomic profiling, and compared diversity, dominance (≥30% relative abundance of a taxon), and differential abundance between high and low anaerobic antibiotic exposure.

Results: The retrospective cohort included 311 patients with relapsed or refractory B-cell malignancies who received anti-CD19 CAR-T therapy between 2018 and 2021, including diffuse large B-cell lymphoma (DLBCL), non-DLBCL non-Hodgkin lymphomas (non-DLBCL NHL), and B-cell acute lymphoblastic leukemia (B-ALL).

By binary clinical classification, anaerobically-active antibiotics in the 4 weeks pre-infusion–but not 4 weeks post- or peri-infusion–were associated with worse progression-free survival (PFS, HR=2.19; 95% CI=1.35–3.57) and OS (HR=2.36; 95% CI=1.21–4.61).

To consider both the anaerobic effect of the antibiotics and their duration, we calculated the cumulative days of AAI score for each patient (DAAI) by multiplying the duration of antibiotic exposure (in days) by its corresponding AAI. Using this quantitative anaerobic activity score, we confirmed that a higher pre-infusion DAAI (>median, “high-DAAI”) was strongly associated with shorter PFS (HR=1.83; 95% CI=1.21–2.77) and OS (HR=1.99; 95% CI=1.14–3.48) compared with patients with a DAAI of 0. Post-infusion DAAI in the top 25% was significantly associated with inferior OS (HR=2.53; 95% CI=1.33–4.83) but not with PFS, revealing an effect that was masked by the binary analysis. Furthermore, a combined peri-infusion DAAI remained significantly associated with inferior OS (HR=2.60; 95% CI=1.31–5.19), highlighting the cumulative detrimental impact of these agents.

In line with our prior findings, exposure to anaerobically-active antibiotics pre-infusion was associated with an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS, HR=2.18; 95% CI=1.15–4.13). A higher pre-infusion DAAI demonstrated a borderline significant association with a greater risk of ICANS (HR=1.80; 95% CI=0.99–3.27). Cytokine release syndrome showed no association with either anaerobically-active antibiotic exposure or DAAI pre-infusion.

In the prospective microbiome cohort (78 NHL patients), high-DAAI patients exhibited a significant decrease in α-diversity (weeks 1–2), altered β-diversity (weeks 1 and 3), and higher microbiome dominance (weeks 0–1) compared with low-DAAI. At week 4, after discontinuing antibiotics, the low-DAAI group was enriched with beneficial, immunomodulatory taxa including Anaerobutyricum hallii–a major short-chain fatty acid producer known to enhance immunotherapy efficacy. Importantly, higher relative abundance of A. hallii at week 4 was associated with prolonged OS.

Conclusions: In this multi-center study, high anaerobic antibiotic burden–captured most robustly by the DAAI score–was associated with worse OS, increased ICANS risk, and loss of A. hallii after CAR-T therapy, highlighting the need for optimized post-infusion antibiotic usage and future microbiome-based interventions.
Jiayi Xie, PhD: No relevant conflicts of interest to declare.